Artwork

Indhold leveret af Proactive Investors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Proactive Investors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Tiziana Life Sciences' Semaglutide Combo Shows Potential in Obesity-Related Liver Inflammation

4:53
 
Del
 

Manage episode 447662698 series 2891889
Indhold leveret af Proactive Investors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Proactive Investors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to share news the company has announced positive research findings showing the anti-inflammatory potential of the company’s nasal anti-CD3 antibody, foralumab, when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. The study, conducted by Dr. Howard Weiner, Selma Boulenouar, PhD, and their team at Brigham and Women’s Hospital, shows the combination significantly improves liver function and reduces inflammation in diet-induced obesity models. The data reveal that nasal anti-CD3 combined with semaglutide not only promotes liver homeostasis but also markedly decreases pro-inflammatory cytokines, suggesting a promising, multifaceted approach to managing obesity and its challenging complications. These findings underline the potential of this therapy as a breakthrough in addressing both obesity and its often treatment-resistant metabolic effects. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #Ozempic #InflammationResearch #MonoclonalAntibody #BiotechNews #IvorElrifi #ClinicalResearch #SPMS #AlzheimersResearch #GLP1 #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

608 episoder

Artwork
iconDel
 
Manage episode 447662698 series 2891889
Indhold leveret af Proactive Investors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Proactive Investors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to share news the company has announced positive research findings showing the anti-inflammatory potential of the company’s nasal anti-CD3 antibody, foralumab, when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. The study, conducted by Dr. Howard Weiner, Selma Boulenouar, PhD, and their team at Brigham and Women’s Hospital, shows the combination significantly improves liver function and reduces inflammation in diet-induced obesity models. The data reveal that nasal anti-CD3 combined with semaglutide not only promotes liver homeostasis but also markedly decreases pro-inflammatory cytokines, suggesting a promising, multifaceted approach to managing obesity and its challenging complications. These findings underline the potential of this therapy as a breakthrough in addressing both obesity and its often treatment-resistant metabolic effects. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #Ozempic #InflammationResearch #MonoclonalAntibody #BiotechNews #IvorElrifi #ClinicalResearch #SPMS #AlzheimersResearch #GLP1 #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

608 episoder

Όλα τα επεισόδια

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning